Sign Up Today and Learn More About Celularity Stock
Invest in or calculate the value of your shares in Celularity or other pre-IPO companies through EquityZen's platform.
About Celularity Stock
Founded
2016
Headquarters
Warren, NJ, US
Total Funding
290M
Industries
Software, Artificial Intelligence, Data and Analytics
Celularity is a developer of therapies designed to treat autoimmune and degenerative diseases, immuno-oncology and functional regeneration. The company's therapies productize allogeneic cells and tissues derived from the postpartum placenta and have the ability to augment immunity and longevity by amplifying the body's ability to fight disease, heal and regenerate itself, enabling patients to begin treatment more quickly, resulting in a better medical outcome.
Celularity Press Mentions
Stay in the know about the latest news on Celularity
Celularity Doses First Patient in Clinical Trial Evaluating CYNK-001 in COVID-19 Patients
news • Sep 08, 2020
Sanuwave announces intent to acquire Celularity’s UltraMist
massdevice • Jun 11, 2020
Unproven Stem Cell Therapy Gets OK for Testing in Coronavirus Patients
New York Times • Apr 02, 2020
First cell treatment to fight the coronavirus awaits FDA approval for clinical trial
CNBC • Mar 31, 2020
Celularity Joins Cast of Drugmakers Targeting New Coronavirus
Wall Streets Journal • Mar 13, 2020
Investors in Celularity
Discover investors in Celularity stock and explore their portfolio companies
Celularity Management
Leadership team at Celularity
Chief Executive Officer
Robert Hariri
Chief Financial Officer
David Beers
Join now and verify your accreditation status to gain access to:
- Celularity current valuation
- Celularity stock price
- Available deals in Celularity and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Celularity Stock
How to invest in Celularity stock?
Accredited investors can buy pre-IPO stock in companies like Celularity through EquityZen funds. These investments are made available by existing Celularity shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Celularity stock?
Shareholders can sell their Celularity stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
